Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study will test the safety of ipilimumab to see what effects, if any, the drug has when
used as maintenance therapy for people with relapsed/refractory multiple myeloma who have
received chemotherapy and allogeneic hematopoietic stem cell transplant (AHCT). The
investigators also want to find out whether giving ipilimumab after chemotherapy and AHCT is
a better way to control the multiple myeloma than chemotherapy and AHCT alone.